

Key: &gt;&gt;&gt; ... marks correct (expected) result

&gt; ... marks conditionally correct (acceptable) result

± ... marks the result not evaluated

N ... number of the results

Nrel ... relative number of the results

## Test

Sample	Group	N	Result	N <sub>rel</sub>
--------	-------	---	--------	------------------

## Set of samples 1 and 2

## (700) AB0 blood group

E1 and S1 (0) not specified	>>>	1	Blood group: 0	0,70 %
(6) APR	>>>	3	Blood group: 0	2,1 %
(14) Bio-Rad	>>>	46	Blood group: 0	32 %
(40) Ortho Clinical Diagnostics	>>>	4	Blood group: 0	2,8 %
(52) Dynex	>>>	2	Blood group: 0	1,4 %
(64) Exbio Olomouc	>>>	11	Blood group: 0	7,7 %
(80) DiaMed	>>>	18	Blood group: 0	13 %
(159) Grifols	>>>	16	Blood group: 0	11 %
(172) Immucor	>>>	20	Blood group: 0	14 %
(173) Sanguin	>>>	11	Blood group: 0	7,7 %
(174) IVT Imuno	>>>	6	Blood group: 0	4,2 %
(203) ANTITOXIN	>>>	2	Blood group: 0	1,4 %
(999) another manufacturer	>>>	2	Blood group: 0	1,4 %
----- Total per sample: n = 142 ----- Success: 100 % -----				

E2 and S2 (0) not specified	>>>	1	Blood group: B	0,70 %
(6) APR	>>>	3	Blood group: B	2,1 %
(14) Bio-Rad	>>>	46	Blood group: B	32 %
(40) Ortho Clinical Diagnostics	>>>	4	Blood group: B	2,8 %
(52) Dynex	>>>	2	Blood group: B	1,4 %
(64) Exbio Olomouc	>>>	11	Blood group: B	7,7 %
(80) DiaMed	>>>	18	Blood group: B	13 %
(159) Grifols	>>>	16	Blood group: B	11 %
(172) Immucor	>>>	20	Blood group: B	14 %
(173) Sanguin	>>>	11	Blood group: B	7,7 %
(174) IVT Imuno	>>>	6	Blood group: B	4,2 %
(203) ANTITOXIN	>>>	2	Blood group: B	1,4 %
(999) another manufacturer	>>>	2	Blood group: B	1,4 %
----- Total per sample: n = 142 ----- Success: 100 % -----				

Total success: 100 %

## (705) Rh D antigen (blood-donor)

E1 and S1 (0) not specified		1	Negative (RhD-)	1,1 %
(6) APR	>>>	3	w/v (RhD weak/variant)	3,2 %
(14) Bio-Rad		4	Negative (RhD-)	4,2 %
	>	4	Positive (RhD+)	4,2 %
	>>>	17	w/v (RhD weak/variant)	18 %
(40) Ortho Clinical Diagnostics		1	Negative (RhD-)	1,1 %
	>>>	1	w/v (RhD weak/variant)	1,1 %
(52) Dynex	>>>	2	w/v (RhD weak/variant)	2,1 %
(64) Exbio Olomouc	>>>	5	w/v (RhD weak/variant)	5,3 %
(80) DiaMed		5	Negative (RhD-)	5,3 %
	>>>	7	w/v (RhD weak/variant)	7,4 %
(159) Grifols		5	Negative (RhD-)	5,3 %
	>	1	Positive (RhD+)	1,1 %
	>>>	3	w/v (RhD weak/variant)	3,2 %
(172) Immucor		6	Negative (RhD-)	6,3 %
	>	2	Positive (RhD+)	2,1 %
	>>>	16	w/v (RhD weak/variant)	17 %
(173) Sanguin		1	Negative (RhD-)	1,1 %
	>>>	3	w/v (RhD weak/variant)	3,2 %
(174) IVT Imuno	>>>	4	w/v (RhD weak/variant)	4,2 %
(203) ANTITOXIN	>>>	3	w/v (RhD weak/variant)	3,2 %
(999) another manufacturer	>>>	1	w/v (RhD weak/variant)	1,1 %
----- Total per sample: n = 95 ----- Success: 76 % -----				

E2 and S2 (0) not specified	>>>	1	Positive (RhD+)	1,1 %
(6) APR	>>>	3	Positive (RhD+)	3,2 %
(14) Bio-Rad	>>>	25	Positive (RhD+)	26 %
(40) Ortho Clinical Diagnostics	>>>	2	Positive (RhD+)	2,1 %
(52) Dynex	>>>	2	Positive (RhD+)	2,1 %
(64) Exbio Olomouc	>>>	5	Positive (RhD+)	5,3 %
(80) DiaMed	>>>	12	Positive (RhD+)	13 %
(159) Grifols	>>>	9	Positive (RhD+)	9,5 %
(172) Immucor	>>>	24	Positive (RhD+)	25 %
(173) Sanguin	>>>	4	Positive (RhD+)	4,2 %
(174) IVT Imuno	>>>	4	Positive (RhD+)	4,2 %

## EQA round: IH4/17 - Blood Group Serology

Dead line: 23.11.2017

## Test

Sample	Group	N	Result	N <sub>rel</sub>
E2 and S2 (203) ANTITOXIN	>>>	3	Positive (RhD+)	3,2 %
(999) another manufacturer	>>>	1	Positive (RhD+)	1,1 %
Total per sample: n = 95		Success: 100 %		
Total success: 76 %				

## (709) Rh D antigen (recipient)

E1 and S1 (0) not specified	>>>	1	Negative (RhD-)	0,76 %
(6) APR	>>>	2	Negative (RhD-)	1,5 %
	>>>	2	w/v (RhD weak/variant)	1,5 %
(14) Bio-Rad	>>>	33	Negative (RhD-)	25 %
	>>>	8	w/v (RhD weak/variant)	6,1 %
(40) Ortho Clinical Diagnostics	>>>	4	Negative (RhD-)	3,0 %
(50) Merck	>>>	1	Negative (RhD-)	0,76 %
(52) Dynex	>>>	1	Negative (RhD-)	0,76 %
	>>>	1	w/v (RhD weak/variant)	0,76 %
(64) Exbio Olomouc	>>>	4	Negative (RhD-)	3,0 %
	>>>	4	w/v (RhD weak/variant)	3,0 %
(80) DiaMed	>>>	14	Negative (RhD-)	11 %
	>>>	2	w/v (RhD weak/variant)	1,5 %
(159) Grifols	>>>	8	Negative (RhD-)	6,1 %
	>>>	6	w/v (RhD weak/variant)	4,5 %
(172) Immucor	>>>	16	Negative (RhD-)	12 %
	>>>	9	w/v (RhD weak/variant)	6,8 %
(173) Sanguin	>>>	6	Negative (RhD-)	4,5 %
	>>>	1	w/v (RhD weak/variant)	0,76 %
(174) IVT Imuno	>>>	3	Negative (RhD-)	2,3 %
	>>>	1	w/v (RhD weak/variant)	0,76 %
(203) ANTITOXIN	>>>	2	Negative (RhD-)	1,5 %
(999) another manufacturer	>>>	2	Negative (RhD-)	1,5 %
	>>>	1	w/v (RhD weak/variant)	0,76 %
Total per sample: n = 132		Success: 100 %		
Total success: 100 %				
E2 and S2 (0) not specified	>>>	1	Positive (RhD+)	0,76 %
(6) APR	>>>	4	Positive (RhD+)	3,0 %
(14) Bio-Rad	>>>	41	Positive (RhD+)	31 %
(40) Ortho Clinical Diagnostics	>>>	4	Positive (RhD+)	3,0 %
(50) Merck	>>>	1	Positive (RhD+)	0,76 %
(52) Dynex	>>>	2	Positive (RhD+)	1,5 %
(64) Exbio Olomouc	>>>	8	Positive (RhD+)	6,1 %
(80) DiaMed	>>>	16	Positive (RhD+)	12 %
(159) Grifols	>>>	14	Positive (RhD+)	11 %
(172) Immucor	>>>	25	Positive (RhD+)	19 %
(173) Sanguin	>>>	7	Positive (RhD+)	5,3 %
(174) IVT Imuno	>>>	4	Positive (RhD+)	3,0 %
(203) ANTITOXIN	>>>	2	Positive (RhD+)	1,5 %
(999) another manufacturer	>>>	3	Positive (RhD+)	2,3 %
Total per sample: n = 132		Success: 100 %		
Total success: 100 %				

## (715) Antigen C

E1 and S1 (14) Bio-Rad	>>>	22	Negative	35 %
		1	Positive	1,6 %
(64) Exbio Olomouc	>>>	2	Negative	3,2 %
(80) DiaMed	>>>	8	Negative	13 %
(159) Grifols	>>>	9	Negative	15 %
(172) Immucor	>>>	11	Negative	18 %
(173) Sanguin	>>>	4	Negative	6,5 %
(174) IVT Imuno	>>>	2	Negative	3,2 %
(203) ANTITOXIN	>>>	2	Negative	3,2 %
(999) another manufacturer	>>>	1	Negative	1,6 %
Total per sample: n = 62		Success: 98 %		
E2 and S2 (14) Bio-Rad	>>>	23	Negative	37 %
(64) Exbio Olomouc	>>>	2	Negative	3,2 %
(80) DiaMed	>>>	8	Negative	13 %
(159) Grifols	>>>	9	Negative	15 %
(172) Immucor	>>>	11	Negative	18 %
(173) Sanguin	>>>	4	Negative	6,5 %
(174) IVT Imuno	>>>	2	Negative	3,2 %
(203) ANTITOXIN	>>>	2	Negative	3,2 %
(999) another manufacturer	>>>	1	Negative	1,6 %
Total per sample: n = 62		Success: 100 %		

## EQA round: IH4/17 - Blood Group Serology

## Test

Sample	Group	N	Result	N <sub>rel</sub>
Total success: 98 %				
<b>(716) Antigen c</b>				
E1 and S1 (14)	Bio-Rad	1	Negative	1,6 %
	>>>	22	Positive	35 %
(64)	Exbio Olomouc	>>>	2 Positive	3,2 %
(80)	DiaMed	>>>	8 Positive	13 %
(159)	Grifols	>>>	9 Positive	15 %
(172)	Immucor	>>>	11 Positive	18 %
(173)	Sanguin	>>>	4 Positive	6,5 %
(174)	IVT Imuno	>>>	2 Positive	3,2 %
(203)	ANTITOXIN	>>>	2 Positive	3,2 %
(999)	another manufacturer	>>>	1 Positive	1,6 %
Total per sample: n = 62		Success: 98 %		
E2 and S2 (14)	Bio-Rad	>>>	23 Positive	37 %
(64)	Exbio Olomouc	>>>	2 Positive	3,2 %
(80)	DiaMed	>>>	8 Positive	13 %
(159)	Grifols	>>>	9 Positive	15 %
(172)	Immucor	>>>	11 Positive	18 %
(173)	Sanguin	>>>	4 Positive	6,5 %
(174)	IVT Imuno	>>>	2 Positive	3,2 %
(203)	ANTITOXIN	>>>	2 Positive	3,2 %
(999)	another manufacturer	>>>	1 Positive	1,6 %
Total per sample: n = 62		Success: 100 %		
Total success: 98 %				
<b>(717) Antigen Cw</b>				
E1 and S1 (14)	Bio-Rad	>>>	13 Negative	27 %
(64)	Exbio Olomouc	>>>	3 Negative	6,1 %
(80)	DiaMed	>>>	5 Negative	10 %
(159)	Grifols	>>>	9 Negative	18 %
(172)	Immucor	>>>	10 Negative	20 %
(173)	Sanguin	>>>	5 Negative	10 %
(174)	IVT Imuno	>>>	2 Negative	4,1 %
(203)	ANTITOXIN	>>>	2 Negative	4,1 %
Total per sample: n = 49		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>>	13 Negative	27 %
(64)	Exbio Olomouc	>>>	3 Negative	6,1 %
(80)	DiaMed	>>>	5 Negative	10 %
(159)	Grifols	>>>	9 Negative	18 %
(172)	Immucor	>>>	10 Negative	20 %
(173)	Sanguin	>>>	5 Negative	10 %
(174)	IVT Imuno	>>>	2 Negative	4,1 %
(203)	ANTITOXIN	>>>	2 Negative	4,1 %
Total per sample: n = 49		Success: 100 %		
Total success: 100 %				
<b>(718) Antigen E</b>				
E1 and S1 (14)	Bio-Rad	>>>	23 Positive	37 %
(64)	Exbio Olomouc	>>>	2 Positive	3,2 %
(80)	DiaMed	>>>	8 Positive	13 %
(159)	Grifols	>>>	9 Positive	15 %
(172)	Immucor	>>>	11 Positive	18 %
(173)	Sanguin	>>>	4 Positive	6,5 %
(174)	IVT Imuno	>>>	2 Positive	3,2 %
(203)	ANTITOXIN	>>>	2 Positive	3,2 %
(999)	another manufacturer	>>>	1 Positive	1,6 %
Total per sample: n = 62		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>>	23 Positive	37 %
(64)	Exbio Olomouc	>>>	2 Positive	3,2 %
(80)	DiaMed	>>>	8 Positive	13 %
(159)	Grifols	>>>	9 Positive	15 %
(172)	Immucor	>>>	11 Positive	18 %
(173)	Sanguin	>>>	4 Positive	6,5 %
(174)	IVT Imuno	>>>	2 Positive	3,2 %
(203)	ANTITOXIN	>>>	2 Positive	3,2 %
(999)	another manufacturer	>>>	1 Positive	1,6 %
Total per sample: n = 62		Success: 100 %		
Total success: 100 %				
<b>(719) Antigen e</b>				
E1 and S1 (14)	Bio-Rad	1	Negative	1,6 %

## EQA round: IH4/17 - Blood Group Serology

Dead line: 23.11.2017

Test			N	Result	N <sub>rel</sub>
Sample	Group				
E1 and S1 (14)	Bio-Rad	>>>	22	Positive	35 %
(64)	Exbio Olomouc	>>>	2	Positive	3,2 %
(80)	DiaMed	>>>	8	Positive	13 %
(159)	Grifols	>>>	9	Positive	15 %
(172)	Immucor	>>>	11	Positive	18 %
(173)	Sanguin	>>>	4	Positive	6,5 %
(174)	IVT Imuno	>>>	2	Positive	3,2 %
(203)	ANTITOXIN	>>>	2	Positive	3,2 %
(999)	another manufacturer	>>>	1	Positive	1,6 %
Total per sample: n = 62		Success: 98 %			
E2 and S2 (14)	Bio-Rad	>>>	22	Negative	35 %
			1	Positive	1,6 %
(64)	Exbio Olomouc	>>>	2	Negative	3,2 %
(80)	DiaMed	>>>	8	Negative	13 %
(159)	Grifols	>>>	9	Negative	15 %
(172)	Immucor	>>>	11	Negative	18 %
(173)	Sanguin	>>>	4	Negative	6,5 %
(174)	IVT Imuno	>>>	2	Negative	3,2 %
(203)	ANTITOXIN	>>>	2	Negative	3,2 %
(999)	another manufacturer	>>>	1	Negative	1,6 %
Total per sample: n = 62		Success: 98 %			
Total success: 97 %					
<b>(720) Antigen K</b>					
E1 and S1 (0)	not specified	>>>	1	Negative	1,5 %
(14)	Bio-Rad	>>>	21	Negative	31 %
(64)	Exbio Olomouc	>>>	1	Negative	1,5 %
(80)	DiaMed	>>>	8	Negative	12 %
(159)	Grifols	>>>	13	Negative	19 %
(172)	Immucor	>>>	11	Negative	16 %
(173)	Sanguin	>>>	5	Negative	7,5 %
(174)	IVT Imuno	>>>	4	Negative	6,0 %
(203)	ANTITOXIN	>>>	2	Negative	3,0 %
(999)	another manufacturer	>>>	1	Negative	1,5 %
Total per sample: n = 67		Success: 100 %			
E2 and S2 (0)	not specified	>>>	1	Negative	1,5 %
(14)	Bio-Rad	>>>	21	Negative	31 %
(64)	Exbio Olomouc	>>>	1	Negative	1,5 %
(80)	DiaMed	>>>	8	Negative	12 %
(159)	Grifols	>>>	13	Negative	19 %
(172)	Immucor	>>>	11	Negative	16 %
(173)	Sanguin	>>>	5	Negative	7,5 %
(174)	IVT Imuno	>>>	4	Negative	6,0 %
(203)	ANTITOXIN	>>>	2	Negative	3,0 %
(999)	another manufacturer	>>>	1	Negative	1,5 %
Total per sample: n = 67		Success: 100 %			
Total success: 100 %					
<b>(721) Antigen k</b>					
E1 and S1 (14)	Bio-Rad	>>>	7	Positive	17 %
(64)	Exbio Olomouc	>>>	5	Positive	12 %
(80)	DiaMed	>>>	3	Positive	7,3 %
(159)	Grifols	>>>	4	Positive	9,8 %
(172)	Immucor	>>>	10	Positive	24 %
(173)	Sanguin	>>>	8	Positive	20 %
(174)	IVT Imuno	>>>	1	Positive	2,4 %
(203)	ANTITOXIN	>>>	2	Positive	4,9 %
(999)	another manufacturer	>>>	1	Positive	2,4 %
Total per sample: n = 41		Success: 100 %			
E2 and S2 (14)	Bio-Rad	>>>	7	Positive	17 %
(64)	Exbio Olomouc	>>>	5	Positive	12 %
(80)	DiaMed	>>>	3	Positive	7,3 %
(159)	Grifols	>>>	4	Positive	9,8 %
(172)	Immucor	>>>	10	Positive	24 %
(173)	Sanguin	>>>	8	Positive	20 %
(174)	IVT Imuno	>>>	1	Positive	2,4 %
(203)	ANTITOXIN	>>>	2	Positive	4,9 %
(999)	another manufacturer	>>>	1	Positive	2,4 %
Total per sample: n = 41		Success: 100 %			
Total success: 100 %					

## EQA round: IH4/17 - Blood Group Serology

## Test

Sample	Group	N	Result	N <sub>rel</sub>
<b>(722) Antigen M</b>				
E1 and S1 (14)	Bio-Rad	>>> 8	Positive	23 %
	(52) Dynex	>>> 2	Positive	5,7 %
	(64) Exbio Olomouc	>>> 2	Positive	5,7 %
	(80) DiaMed	>>> 4	Positive	11 %
	(159) Grifols	>>> 3	Positive	8,6 %
	(172) Immucor	>>> 11	Positive	31 %
	(173) Sanguin	>>> 2	Positive	5,7 %
	(203) ANTITOXIN	>>> 2	Positive	5,7 %
	(999) another manufacturer	>>> 1	Positive	2,9 %
Total per sample: n = 35		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>> 8	Positive	23 %
	(52) Dynex	>>> 2	Positive	5,7 %
	(64) Exbio Olomouc	>>> 2	Positive	5,7 %
	(80) DiaMed	>>> 4	Positive	11 %
	(159) Grifols	>>> 3	Positive	8,6 %
	(172) Immucor	>>> 11	Positive	31 %
	(173) Sanguin	>>> 2	Positive	5,7 %
	(203) ANTITOXIN	>>> 2	Positive	5,7 %
	(999) another manufacturer	>>> 1	Positive	2,9 %
Total per sample: n = 35		Success: 100 %		
Total success: 100 %				

**(723) Antigen N**

E1 and S1 (14)	Bio-Rad	>>> 8	Negative	24 %
	(52) Dynex	>>> 1	Positive	3,0 %
	(64) Exbio Olomouc	>>> 1	Negative	3,0 %
	(80) DiaMed	>>> 4	Negative	12 %
	(159) Grifols	>>> 4	Negative	12 %
	(172) Immucor	>>> 8	Negative	24 %
	(173) Sanguin	>>> 3	Negative	9,1 %
	(174) IVT Imuno	>>> 1	Negative	3,0 %
	(203) ANTITOXIN	>>> 2	Negative	6,1 %
	(999) another manufacturer	>>> 1	Negative	3,0 %
Total per sample: n = 33		Success: 97 %		
E2 and S2 (14)	Bio-Rad	>>> 8	Negative	24 %
	(52) Dynex	>>> 1	Negative	3,0 %
	(64) Exbio Olomouc	>>> 1	Negative	3,0 %
	(80) DiaMed	>>> 4	Negative	12 %
	(159) Grifols	>>> 4	Negative	12 %
	(172) Immucor	>>> 8	Negative	24 %
	(173) Sanguin	>>> 3	Negative	9,1 %
	(174) IVT Imuno	>>> 1	Negative	3,0 %
	(203) ANTITOXIN	>>> 2	Negative	6,1 %
	(999) another manufacturer	>>> 1	Negative	3,0 %
Total per sample: n = 33		Success: 100 %		
Total success: 97 %				

**(724) Antigen S**

E1 and S1 (14)	Bio-Rad	>>> 1	Negative	2,9 %
	(50) Merck	>>> 8	Positive	23 %
	(52) Dynex	>>> 1	Positive	2,9 %
	(52) Dynex	>>> 2	Positive	5,7 %
	(64) Exbio Olomouc	>>> 2	Positive	5,7 %
	(80) DiaMed	>>> 4	Positive	11 %
	(159) Grifols	>>> 3	Positive	8,6 %
	(172) Immucor	>>> 5	Positive	14 %
	(173) Sanguin	>>> 5	Positive	14 %
	(174) IVT Imuno	>>> 3	Positive	8,6 %
	(203) ANTITOXIN	>>> 1	Positive	2,9 %
Total per sample: n = 35		Success: 97 %		
E2 and S2 (14)	Bio-Rad	>>> 9	Positive	26 %
	(50) Merck	>>> 1	Positive	2,9 %
	(52) Dynex	>>> 2	Positive	5,7 %
	(64) Exbio Olomouc	>>> 2	Positive	5,7 %
	(80) DiaMed	>>> 4	Positive	11 %
	(159) Grifols	>>> 3	Positive	8,6 %
	(172) Immucor	>>> 5	Positive	14 %
	(173) Sanguin	>>> 5	Positive	14 %
	(174) IVT Imuno	>>> 3	Positive	8,6 %
	(203) ANTITOXIN	>>> 1	Positive	2,9 %

## EQA round: IH4/17 - Blood Group Serology

Dead line: 23.11.2017

## Test

Sample	Group	N	Result	N <sub>rel</sub>
Total per sample: n = 35		Success: 100 %		
Total success: 97 %				

**(725) Antigen s**

E1 and S1 (14) Bio-Rad	>>>	8	Negative	23 %
		1	Positive	2,9 %
(64) Exbio Olomouc	>>>	4	Negative	11 %
(80) DiaMed	>>>	4	Negative	11 %
(159) Grifols	>>>	3	Negative	8,6 %
(172) Immucor	>>>	5	Negative	14 %
(173) Sanguin	>>>	6	Negative	17 %
(174) IVT Imuno	>>>	3	Negative	8,6 %
(203) ANTITOXIN	>>>	1	Negative	2,9 %
Total per sample: n = 35		Success: 97 %		

E2 and S2 (14) Bio-Rad	>>>	9	Positive	26 %
(64) Exbio Olomouc	>>>	4	Positive	11 %
(80) DiaMed	>>>	4	Positive	11 %
(159) Grifols	>>>	3	Positive	8,6 %
(172) Immucor	>>>	5	Positive	14 %
(173) Sanguin	>>>	6	Positive	17 %
(174) IVT Imuno	>>>	3	Positive	8,6 %
(203) ANTITOXIN	>>>	1	Positive	2,9 %
Total per sample: n = 35		Success: 100 %		
Total success: 97 %				

**(726) Antigen P1**

E1 and S1 (14) Bio-Rad	>>>	7	Positive	26 %
(64) Exbio Olomouc	>>>	3	Positive	11 %
(80) DiaMed	>>>	2	Positive	7,4 %
(172) Immucor	>>>	5	Positive	19 %
(173) Sanguin	>>>	1	Negative	3,7 %
	>>>	7	Positive	26 %
(203) ANTITOXIN	>>>	2	Positive	7,4 %
Total per sample: n = 27		Success: 96 %		

E2 and S2 (14) Bio-Rad	>>>	7	Positive	26 %
(64) Exbio Olomouc	>>>	3	Positive	11 %
(80) DiaMed	>>>	2	Positive	7,4 %
(172) Immucor	>>>	5	Positive	19 %
(173) Sanguin	>>>	8	Positive	30 %
(203) ANTITOXIN	>>>	2	Positive	7,4 %
Total per sample: n = 27		Success: 100 %		
Total success: 96 %				

**(727) Antigen Fya**

E1 and S1 (14) Bio-Rad		1	Negative	2,9 %
	>>>	8	Positive	24 %
(64) Exbio Olomouc	>>>	3	Positive	8,8 %
(80) DiaMed	>>>	4	Positive	12 %
(159) Grifols	>>>	3	Positive	8,8 %
(172) Immucor	>>>	7	Positive	21 %
(173) Sanguin	>>>	6	Positive	18 %
(174) IVT Imuno	>>>	1	Positive	2,9 %
(203) ANTITOXIN	>>>	1	Positive	2,9 %
Total per sample: n = 34		Success: 97 %		

E2 and S2 (14) Bio-Rad	>>>	9	Positive	26 %
(64) Exbio Olomouc	>>>	3	Positive	8,8 %
(80) DiaMed	>>>	4	Positive	12 %
(159) Grifols	>>>	3	Positive	8,8 %
(172) Immucor	>>>	7	Positive	21 %
(173) Sanguin	>>>	6	Positive	18 %
(174) IVT Imuno	>>>	1	Positive	2,9 %
(203) ANTITOXIN	>>>	1	Positive	2,9 %
Total per sample: n = 34		Success: 100 %		
Total success: 97 %				

**(728) Antigen Fyb**

E1 and S1 (14) Bio-Rad	>>>	8	Negative	24 %
		1	Positive	2,9 %
(64) Exbio Olomouc	>>>	3	Negative	8,8 %
(80) DiaMed	>>>	4	Negative	12 %
(159) Grifols	>>>	3	Negative	8,8 %
(172) Immucor	>>>	7	Negative	21 %
(173) Sanguin	>>>	6	Negative	18 %

## EQA round: IH4/17 - Blood Group Serology

Dead line: 23.11.2017

## Test

Sample	Group	N	Result	N <sub>rel</sub>
E1 and S1 (174)	IVT Imuno	>>>	1 Negative	2,9%
	(203) ANTITOXIN	>>>	1 Negative	2,9%
Total per sample: n = 34			Success: 97 %	
E2 and S2 (14)	Bio-Rad	>>>	9 Positive	26%
	(64) Exbio Olomouc	>>>	3 Positive	8,8%
	(80) DiaMed	>>>	4 Positive	12%
	(159) Grifols	>>>	3 Positive	8,8%
	(172) Immucor	>>>	7 Positive	21%
	(173) Sanguin	>>>	6 Positive	18%
	(174) IVT Imuno	>>>	1 Positive	2,9%
	(203) ANTITOXIN	>>>	1 Positive	2,9%
Total per sample: n = 34			Success: 100 %	
Total success: 97 %				

## (729) Antigen Jka

E1 and S1 (14)	Bio-Rad	>>>	9 Positive	26%
	(50) Merck	>>>	1 Positive	2,9%
	(52) Dynex	>>>	2 Positive	5,7%
	(64) Exbio Olomouc	>>>	2 Positive	5,7%
	(80) DiaMed	>>>	4 Positive	11%
	(159) Grifols	>>>	3 Positive	8,6%
	(172) Immucor	>>>	5 Positive	14%
	(173) Sanguin	>>>	5 Positive	14%
	(174) IVT Imuno	>>>	2 Positive	5,7%
	(203) ANTITOXIN	>>>	2 Positive	5,7%
	Total per sample: n = 35			Success: 100 %
E2 and S2 (14)	Bio-Rad	>>>	9 Negative	26%
	(50) Merck	>>>	1 Negative	2,9%
	(52) Dynex	>>>	2 Negative	5,7%
	(64) Exbio Olomouc	>>>	2 Negative	5,7%
	(80) DiaMed	>>>	4 Negative	11%
	(159) Grifols	>>>	3 Negative	8,6%
	(172) Immucor	>>>	5 Negative	14%
	(173) Sanguin	>>>	5 Negative	14%
	(174) IVT Imuno	>>>	2 Negative	5,7%
	(203) ANTITOXIN	>>>	2 Negative	5,7%
Total per sample: n = 35			Success: 100 %	
Total success: 100 %				

## (730) Antigen Jkb

E1 and S1 (14)	Bio-Rad	>>>	9 Negative	26%
	(50) Merck	>>>	1 Negative	2,9%
	(52) Dynex	>>>	3 Negative	8,6%
	(64) Exbio Olomouc	>>>	2 Negative	5,7%
	(80) DiaMed	>>>	4 Negative	11%
	(159) Grifols	>>>	3 Negative	8,6%
	(172) Immucor	>>>	5 Negative	14%
	(173) Sanguin	>>>	5 Negative	14%
	(174) IVT Imuno	>>>	1 Negative	2,9%
	(203) ANTITOXIN	>>>	2 Negative	5,7%
	Total per sample: n = 35			Success: 100 %
E2 and S2 (14)	Bio-Rad	>>>	9 Positive	26%
	(50) Merck	>>>	1 Positive	2,9%
	(52) Dynex	>>>	3 Positive	8,6%
	(64) Exbio Olomouc	>>>	2 Positive	5,7%
	(80) DiaMed	>>>	4 Positive	11%
	(159) Grifols	>>>	3 Positive	8,6%
	(172) Immucor	>>>	5 Positive	14%
	(173) Sanguin	>>>	5 Positive	14%
	(174) IVT Imuno	>>>	1 Positive	2,9%
	(203) ANTITOXIN	>>>	2 Positive	5,7%
Total per sample: n = 35			Success: 100 %	
Total success: 100 %				

## (731) Antigen Lua

E1 and S1 (14)	Bio-Rad	>>>	7 Negative	26%
	(64) Exbio Olomouc	>>>	3 Negative	11%
	(80) DiaMed	>>>	3 Negative	11%
	(159) Grifols	>>>	2 Negative	7,4%
	(172) Immucor	>>>	5 Negative	19%
	(173) Sanguin	>>>	4 Negative	15%
	(203) ANTITOXIN	>>>	1 Negative	3,7%

## EQA round: IH4/17 - Blood Group Serology

Dead line: 23.11.2017

## Test

Sample	Group	N	Result	N <sub>rel</sub>
E1 and S1 (999) another manufacturer		>>> 2	Negative	7,4 %
Total per sample: n = 27		Success: 100 %		
E2 and S2 (14) Bio-Rad		>>> 7	Negative	26 %
(64) Exbio Olomouc		>>> 3	Negative	11 %
(80) DiaMed		>>> 3	Negative	11 %
(159) Grifols		>>> 2	Negative	7,4 %
(172) Immucor		>>> 5	Negative	19 %
(173) Sanguin		>>> 4	Negative	15 %
(203) ANTITOXIN		>>> 1	Negative	3,7 %
(999) another manufacturer		>>> 2	Negative	7,4 %
Total per sample: n = 27		Success: 100 %		
Total success: 100 %				

## (732) Antigen Lub

E1 and S1 (6) APR		>>> 1	Positive	3,8 %
(14) Bio-Rad		>>> 7	Positive	27 %
(52) Dynex		>>> 1	Positive	3,8 %
(64) Exbio Olomouc		>>> 2	Positive	7,7 %
(80) DiaMed		>>> 2	Positive	7,7 %
(159) Grifols		>>> 2	Positive	7,7 %
(172) Immucor		>>> 4	Positive	15 %
(173) Sanguin		>>> 2	Positive	7,7 %
(203) ANTITOXIN		>>> 1	Positive	3,8 %
(999) another manufacturer		>>> 4	Positive	15 %
Total per sample: n = 26		Success: 100 %		
E2 and S2 (6) APR		>>> 1	Positive	3,8 %
(14) Bio-Rad		>>> 7	Positive	27 %
(52) Dynex		>>> 1	Positive	3,8 %
(64) Exbio Olomouc		>>> 2	Positive	7,7 %
(80) DiaMed		>>> 2	Positive	7,7 %
(159) Grifols		>>> 2	Positive	7,7 %
(172) Immucor		>>> 4	Positive	15 %
(173) Sanguin		>>> 2	Positive	7,7 %
(203) ANTITOXIN		>>> 1	Positive	3,8 %
(999) another manufacturer		>>> 4	Positive	15 %
Total per sample: n = 26		Success: 100 %		
Total success: 100 %				

## (733) Antigen Lea

E1 and S1 (14) Bio-Rad		>>> 8	Negative	27 %	
			2	Positive	6,7 %
(50) Merck		>>> 1	Negative	3,3 %	
(52) Dynex		>>> 1	Negative	3,3 %	
(64) Exbio Olomouc		>>> 2	Negative	6,7 %	
(80) DiaMed		>>> 4	Negative	13 %	
(172) Immucor		>>> 8	Negative	27 %	
(173) Sanguin		>>> 1	Negative	3,3 %	
(174) IVT Imuno		>>> 1	Negative	3,3 %	
(203) ANTITOXIN		>>> 2	Negative	6,7 %	
Total per sample: n = 30		Success: 93 %			
E2 and S2 (14) Bio-Rad		>>> 10	Positive	33 %	
(50) Merck		>>> 1	Positive	3,3 %	
(52) Dynex		>>> 1	Positive	3,3 %	
(64) Exbio Olomouc		>>> 2	Positive	6,7 %	
(80) DiaMed		>>> 4	Positive	13 %	
(172) Immucor		>>> 8	Positive	27 %	
(173) Sanguin		>>> 1	Positive	3,3 %	
(174) IVT Imuno		>>> 1	Positive	3,3 %	
(203) ANTITOXIN		>>> 2	Positive	6,7 %	
Total per sample: n = 30		Success: 100 %			
Total success: 93 %					

## (734) Antigen Leb

E1 and S1 (14) Bio-Rad			1	Negative	3,3 %
		>>> 9	Positive	30 %	
(50) Merck		>>> 1	Positive	3,3 %	
(52) Dynex		>>> 1	Positive	3,3 %	
(64) Exbio Olomouc		>>> 2	Positive	6,7 %	
(80) DiaMed		>>> 4	Positive	13 %	
(172) Immucor		>>> 7	Positive	23 %	
(173) Sanguin		>>> 2	Positive	6,7 %	



## EQA round: IH4/17 - Blood Group Serology

Dead line: 23.11.2017

## Test

Sample	Group	N	Result	N <sub>rel</sub>
E1 and S1 (174)	IVT Imuno	>>> 1	Positive	3,3 %
	(203) ANTITOXIN	>>> 2	Positive	6,7 %
Total per sample: n = 30		Success: 97 %		
E2 and S2 (14)	Bio-Rad	>>> 10	Negative	33 %
	(50) Merck	>>> 1	Negative	3,3 %
	(52) Dynex	>>> 1	Negative	3,3 %
	(64) Exbio Olomouc	>>> 2	Negative	6,7 %
	(80) DiaMed	>>> 4	Negative	13 %
	(172) Immucor	>>> 7	Negative	23 %
	(173) Sanguin	>>> 2	Negative	6,7 %
	(174) IVT Imuno	>>> 1	Negative	3,3 %
	(203) ANTITOXIN	>>> 2	Negative	6,7 %
Total per sample: n = 30		Success: 100 %		
Total success: 97 %				

## (737) Direct Coombs (antiglobulin) test

E1 and S1 (6)	APR	>>> 1	Negative	0,84 %	
	(14) Bio-Rad	>>> 58	Negative	49 %	
			1	Positive	0,84 %
	(40) Ortho Clinical Diagnostics	>>> 4	Negative	3,4 %	
	(64) Exbio Olomouc	>>> 2	Negative	1,7 %	
	(80) DiaMed	>>> 29	Negative	24 %	
	(159) Grifols	>>> 19	Negative	16 %	
	(172) Immucor	>>> 2	Negative	1,7 %	
	(173) Sanguin	>>> 1	Negative	0,84 %	
	(174) IVT Imuno	>>> 1	Negative	0,84 %	
(203) ANTITOXIN	>>> 1	Negative	0,84 %		
Total per sample: n = 119		Success: 99 %			
E2 and S2 (6)	APR	>>> 1	Negative	0,84 %	
	(14) Bio-Rad	>>> 59	Negative	50 %	
	(40) Ortho Clinical Diagnostics	>>> 4	Negative	3,4 %	
	(64) Exbio Olomouc	>>> 2	Negative	1,7 %	
	(80) DiaMed	>>> 29	Negative	24 %	
	(159) Grifols	>>> 19	Negative	16 %	
	(172) Immucor	>>> 2	Negative	1,7 %	
	(173) Sanguin	>>> 1	Negative	0,84 %	
	(174) IVT Imuno	>>> 1	Negative	0,84 %	
(203) ANTITOXIN	>>> 1	Negative	0,84 %		
Total per sample: n = 119		Success: 100 %			
Total success: 99 %					

## (741) Antibody screening (IAT, blood donor)

E1 and S1 (0) not specified		>>> 1	Positive	1,2 %
	(6) APR	>>> 2	Positive	2,4 %
	(14) Bio-Rad	>>> 34	Positive	40 %
	(40) Ortho Clinical Diagnostics	>>> 1	Positive	1,2 %
	(64) Exbio Olomouc	>>> 1	Positive	1,2 %
	(80) DiaMed	>>> 22	Positive	26 %
	(159) Grifols	>>> 9	Positive	11 %
	(172) Immucor	>>> 14	Positive	17 %
Total per sample: n = 84		Success: 100 %		
E2 and S2 (0) not specified		>>> 1	Positive	1,2 %
	(6) APR	>>> 2	Positive	2,4 %
	(14) Bio-Rad	>>> 34	Positive	40 %
	(40) Ortho Clinical Diagnostics	>>> 1	Positive	1,2 %
	(64) Exbio Olomouc	>>> 1	Positive	1,2 %
	(80) DiaMed	>>> 22	Positive	26 %
	(159) Grifols	>>> 9	Positive	11 %
	(172) Immucor	>>> 14	Positive	17 %
Total per sample: n = 84		Success: 100 %		
Total success: 100 %				

## (743) Antibody screening (IAT, recipient)

E1 and S1 (6) APR		>>> 2	Positive	1,6 %
	(14) Bio-Rad	>>> 63	Positive	50 %
	(40) Ortho Clinical Diagnostics	>>> 4	Positive	3,2 %
	(80) DiaMed	>>> 30	Positive	24 %
	(159) Grifols	>>> 19	Positive	15 %
	(172) Immucor	>>> 8	Positive	6,3 %
Total per sample: n = 126		Success: 100 %		
E2 and S2 (6) APR		>>> 2	Positive	1,6 %

## EQA round: IH4/17 - Blood Group Serology

Dead line: 23.11.2017

Test		N	Result	N <sub>rel</sub>
Sample	Group			
E2 and S2 (14)	Bio-Rad	>>> 63	Positive	50 %
	(40) Ortho Clinical Diagnostics	>>> 4	Positive	3,2 %
	(80) DiaMed	>>> 30	Positive	24 %
	(159) Grifols	>>> 19	Positive	15 %
	(172) Immucor	>>> 8	Positive	6,3 %
Total per sample: n = 126		Success: 100 %		
Total success: 100 %				
<b>(745) Antibody screening (IAT, pregnant)</b>				
E1 and S1 (6)	APR	>>> 2	Positive	1,9 %
	(14) Bio-Rad	>>> 45	Positive	43 %
	(40) Ortho Clinical Diagnostics	>>> 4	Positive	3,8 %
	(64) Exbio Olomouc	>>> 1	Positive	0,96 %
	(80) DiaMed	>>> 24	Positive	23 %
	(159) Grifols	>>> 20	Positive	19 %
	(172) Immucor	>>> 8	Positive	7,7 %
Total per sample: n = 104		Success: 100 %		
E2 and S2 (6)	APR	>>> 2	Positive	1,9 %
	(14) Bio-Rad	>>> 45	Positive	43 %
	(40) Ortho Clinical Diagnostics	>>> 4	Positive	3,8 %
	(64) Exbio Olomouc	>>> 1	Positive	0,96 %
	(80) DiaMed	>>> 24	Positive	23 %
	(159) Grifols	>>> 20	Positive	19 %
	(172) Immucor	>>> 8	Positive	7,7 %
Total per sample: n = 104		Success: 100 %		
Total success: 100 %				
<b>(747) Antibody screening (enzyme test)</b>				
E1 and S1 (14)	Bio-Rad	>>> 49	Positive	47 %
	(40) Ortho Clinical Diagnostics	>>> 1	Positive	0,96 %
	(80) DiaMed	>>> 28	Positive	27 %
	(159) Grifols	>>> 22	Positive	21 %
	(172) Immucor	>>> 4	Positive	3,8 %
Total per sample: n = 104		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>> 49	Positive	47 %
	(40) Ortho Clinical Diagnostics	>>> 1	Positive	0,96 %
	(80) DiaMed	>>> 28	Positive	27 %
	(159) Grifols	>>> 22	Positive	21 %
	(172) Immucor	>>> 4	Positive	3,8 %
Total per sample: n = 104		Success: 100 %		
Total success: 100 %				
<b>(750) Antibody identification</b>				
E1 and S1 (0)	not specified	>>> 42	anti-D	100 %
Total per sample: n = 42		Success: 100 %		
E2 and S2 (0)	not specified	>>> 1	Not specified	2,4 %
		>>> 32	anti-C; anti-e	76 %
		> 1	anti-C; anti-e; anti-Cw	2,4 %
		> 8	anti-e	19 %
Total per sample: n = 42		Success: 98 %		
Total success: 98 %				
<b>(752) Antibody titre, Sample 1: 1st antibody</b>				
E1 and S1 (0)	not specified	± 2	titre 16	5,9 %
		± 4	titre 32	12 %
		± 6	titre 64	18 %
		± 15	titre 128	44 %
		± 5	titre 256	15 %
		± 2	titre 512	5,9 %
Total per sample: n = 34		Success (only evaluated results):	evaluation	
<b>(756) Antibody titre, Sample 2: 1st antibody</b>				
E2 and S2 (0)	not specified	± 1	titre 0 (not measurable)	5,3 %
		± 1	titre 1	5,3 %
		± 1	titre 8	5,3 %
		± 3	titre 16	16 %
		± 4	titre 32	21 %
		± 3	titre 64	16 %
		± 5	titre 128	26 %
		± 1	titre 256	5,3 %
Total per sample: n = 19		Success (only evaluated results):	evaluation	

## Test

Sample	Group	N	Result	N <sub>rel</sub>
<b>(757) Antibody titre, Sample 2: 2nd antibody</b>				
E2 and S2 (0) not specified		± 6	titre 0 (not measurable)	19 %
		± 3	titre 1	9,4 %
		± 4	titre 2	13 %
		± 3	titre 4	9,4 %
		± 8	titre 8	25 %
		± 6	titre 16	19 %
		± 2	titre 32	6,3 %
Total per sample: n = 32		Success (only evaluated results): evaluation		

**Set of samples 3****(760) Crossmatch**

S1	All results	1	Crossmatch not successful	0,88 %
		>>> 113	Crossmatch successful	99 %
Total per sample: n = 114		Success: 99 %		
S2	All results	5	Crossmatch not successful	4,4 %
		>>> 109	Crossmatch successful	96 %
Total per sample: n = 114		Success: 96 %		
Total success: 96 %				

**(761) Crossmatch (segment K1)**

S1	(0) not specified	>>> 114	Positive test	100 %
Total per sample: n = 114		Success: 100 %		
S2	(0) not specified	5	Negative test	4,4 %
		>>> 109	Positive test	96 %
Total per sample: n = 114		Success: 96 %		
Total success: 96 %				

**(762) Serve transfusion product (segment K1)**

S1	(0) not specified	± 114	Impossible, risk of haemolysis	100 %
Total per sample: n = 114		Success (only evaluated results): evaluation		
S2	(0) not specified	± 109	Impossible, risk of haemolysis	96 %
		± 4	Decision depends on results of other tests not performed in our laboratory	3,5 %
		± 1	Possible	0,88 %
Total per sample: n = 114		Success (only evaluated results): evaluation		

**(764) Crossmatch (segment K2)**

S1	(0) not specified	>>> 113	Negative test	99 %
		1	Positive test	0,88 %
Total per sample: n = 114		Success: 99 %		
S2	(0) not specified	>>> 114	Positive test	100 %
Total per sample: n = 114		Success: 100 %		
Total success: 99 %				

**(765) Serve transfusion product (segment K2)**

S1	(0) not specified	± 2	Impossible, risk of haemolysis	1,8 %
		± 56	Decision depends on results of other tests not performed in our laboratory	49 %
		± 29	Only if more suitable products are not available	25 %
		± 27	Possible	24 %
Total per sample: n = 114		Success (only evaluated results): evaluation		
S2	(0) not specified	± 114	Impossible, risk of haemolysis	100 %
Total per sample: n = 114		Success (only evaluated results): evaluation		